Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C brings in $69mm for Pearl Therapeutics

Executive Summary

Vatera Healthcare Partners has led Pearl Therapeutics Inc.'s (combination therapies for chronic respiratory diseases) $69mm Series C venture round. (Vetera will contribute one board member and appoint a board observer.) Current shareholders Clarus Ventures, New Leaf Venture Partners, and 5AM Ventures also participated. The funds will be used to complete the Phase IIb study for Pearl's lead drug candidate, PT003 (glycopyrrolate/formoterol), a bronchodilator for COPD; Phase III should start before the end of 2012. The company has brought in $102.5mm since 2007.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies